MindWalk (NASDAQ:HYFT) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of MindWalk (NASDAQ:HYFT) from a sell rating to a hold rating in a research report sent to investors on Saturday morning.

Several other analysts have also issued reports on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of MindWalk in a research report on Wednesday, July 15th. HC Wainwright reiterated a “buy” rating on shares of MindWalk in a research report on Monday, July 20th. Finally, Zacks Research cut shares of MindWalk from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 28th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $5.00.

MindWalk Trading Down 5.7%

MindWalk stock opened at $1.33 on Friday. The business has a 50-day simple moving average of $1.46 and a two-hundred day simple moving average of $1.38. The company has a market cap of $62.12 million, a P/E ratio of -6.05 and a beta of 0.84. MindWalk has a 52-week low of $0.99 and a 52-week high of $3.25. The company has a quick ratio of 2.72, a current ratio of 2.80 and a debt-to-equity ratio of 0.26.

MindWalk (NASDAQ:HYFT) last released its quarterly earnings results on Wednesday, July 22nd. The company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.01). MindWalk had a negative net margin of 89.65% and a negative return on equity of 92.61%. The business had revenue of $3.03 million for the quarter. Analysts predict that MindWalk will post -0.21 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in HYFT. Virtu Financial LLC bought a new position in shares of MindWalk during the 4th quarter valued at approximately $51,000. GSA Capital Partners LLP purchased a new stake in MindWalk in the 2nd quarter worth approximately $55,000. Bridgeway Capital Management LLC bought a new stake in MindWalk during the 4th quarter worth approximately $91,000. Bank of Montreal Can raised its stake in MindWalk by 81.0% during the 4th quarter. Bank of Montreal Can now owns 54,750 shares of the company’s stock worth $100,000 after acquiring an additional 24,500 shares during the period. Finally, XTX Topco Ltd raised its stake in MindWalk by 118.6% during the 4th quarter. XTX Topco Ltd now owns 81,721 shares of the company’s stock worth $149,000 after acquiring an additional 44,331 shares during the period. Institutional investors own 6.70% of the company’s stock.

MindWalk Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.